Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.4K citations

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

Fred R. Hirsch, Marileila Varella‐Garcia, Paul A. Bunn et al. · Journal of Clinical Oncology · 2003 · 1.5K citations

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Metronomic Therapy, Phase Iii Trial +7

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

Federico Cappuzzo, Tudor–Eliade Ciuleanu, Lilia Stelmakh et al. · The Lancet Oncology · 2010 · 1.2K citations · Full text

Placebo-controlled Phase 3, Maintenance Treatment, Medicine +7